Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

    NEXT STORY
    Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan
    PREV STORY
    Teleflex continues to deliver COMPLETE confidence with new Arrow® ErgoPack® Complete MAC, PSI Systems
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017

    HALIFAX, Nova Scotia, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

    author_avatar
    NASDAQ Market News

    Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

     Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV ...

    author_avatar
    NASDAQ Market News

    Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism

    author_avatar
    NASDAQ Market News